Literature DB >> 16286610

The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17.

Matthew D Davis1, Ronald E Gangnon, Li-Yin Lee, Larry D Hubbard, Barbara E K Klein, Ronald Klein, Frederick L Ferris, Susan B Bressler, Roy C Milton.   

Abstract

OBJECTIVE: To develop a fundus photographic severity scale for age-related macular degeneration (AMD).
METHODS: In the Age-Related Eye Disease Study, stereoscopic color fundus photographs were taken at baseline, at the 2-year follow-up visit, and annually thereafter. Photographs were graded for drusen characteristics (size, type, area), pigmentary abnormalities (increased pigment, depigmentation, geographic atrophy), and presence of abnormalities characteristic of neovascular AMD (retinal pigment epithelial detachment, serous or hemorrhagic sensory retinal detachment, subretinal or sub-retinal pigment epithelial hemorrhage, subretinal fibrous tissue). Advanced AMD was defined as presence of 1 or more neovascular AMD abnormalities, photocoagulation for AMD, or geographic atrophy involving the center of the macula. We explored associations among right eyes of 3212 participants between severity of drusen characteristics and pigmentary abnormalities at baseline and development of advanced AMD within 5 years of follow-up.
RESULTS: A 9-step severity scale that combines a 6-step drusen area scale with a 5-step pigmentary abnormality scale was developed, on which the 5-year risk of advanced AMD increased progressively from less than 1% in step 1 to about 50% in step 9. Among the 334 eyes that had at least a 3-step progression on the scale between the baseline and 5-year visits, almost half showed stepwise progression through intervening severity levels at intervening visits. Replicate gradings showed agreement within 1 step on the scale in 87% of eyes.
CONCLUSIONS: The scale provides convenient risk categories and has acceptable reproducibility. Progression along it may prove to be useful as a surrogate for progression to advanced AMD.

Entities:  

Mesh:

Year:  2005        PMID: 16286610      PMCID: PMC1472813          DOI: 10.1001/archopht.123.11.1484

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  12 in total

1.  Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3.

Authors: 
Journal:  Ophthalmology       Date:  2000-12       Impact factor: 12.079

2.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-10

3.  A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-10

4.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; S C Jensen; S M Meuer
Journal:  Ophthalmology       Date:  1997-01       Impact factor: 12.079

5.  The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-11       Impact factor: 5.258

6.  Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1993-09

7.  Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort.

Authors:  Jie Jin Wang; Suriya Foran; Wayne Smith; Paul Mitchell
Journal:  Arch Ophthalmol       Date:  2003-05

8.  The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study.

Authors:  Redmer van Leeuwen; Caroline C W Klaver; Johannes R Vingerling; Albert Hofman; Paulus T V M de Jong
Journal:  Arch Ophthalmol       Date:  2003-04

9.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study.

Authors:  Ronald Klein; Barbara E K Klein; Sandra C Tomany; Stacy M Meuer; Guan-Hua Huang
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

10.  The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  1995-01
View more
  239 in total

Review 1.  Aging and vision.

Authors:  Cynthia Owsley
Journal:  Vision Res       Date:  2010-10-23       Impact factor: 1.886

2.  Automated discovery and quantification of image-based complex phenotypes: a twin study of drusen phenotypes in age-related macular degeneration.

Authors:  Gwenole Quellec; Stephen R Russell; Johanna M Seddon; Robyn Reynolds; Todd Scheetz; Vinit B Mahajan; Edwin M Stone; Michael D Abràmoff
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-25       Impact factor: 4.799

3.  Is drusen area really so important? An assessment of risk of conversion to neovascular AMD based on computerized measurements of drusen.

Authors:  Thomas R Friberg; Richard A Bilonick; Peter Brennen
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-02       Impact factor: 4.799

Review 4.  The retinal pigment epithelium in health and disease.

Authors:  J R Sparrow; D Hicks; C P Hamel
Journal:  Curr Mol Med       Date:  2010-12       Impact factor: 2.222

5.  Photoreceptor dysfunction in early and intermediate age-related macular degeneration assessed with mfERG and spectral domain OCT.

Authors:  Shasha Yang; Chengguo Zuo; Hui Xiao; Lan Mi; Guangwei Luo; Xiaoyu Xu; Xing Liu
Journal:  Doc Ophthalmol       Date:  2016-01-11       Impact factor: 2.379

6.  ASSOCIATION BETWEEN VISUAL FUNCTION AND SUBRETINAL DRUSENOID DEPOSITS IN NORMAL AND EARLY AGE-RELATED MACULAR DEGENERATION EYES.

Authors:  David Neely; Anna V Zarubina; Mark E Clark; Carrie E Huisingh; Gregory R Jackson; Yuhua Zhang; Gerald McGwin; Christine A Curcio; Cynthia Owsley
Journal:  Retina       Date:  2017-07       Impact factor: 4.256

7.  SAVE-AMD: Safety of VEGF Inhibitors in Age-Related Macular Degeneration.

Authors:  Frank Enseleit; Stephan Michels; Isabella Sudano; Marc Stahel; Sandrine Zweifel; Oliver Schlager; Matthias Becker; Stephan Winnik; Matthias Nägele; Andreas J Flammer; Michel Neidhart; Nicole Graf; Christian M Matter; Burkhardt Seifert; Thomas F Lüscher; Frank Ruschitzka
Journal:  Ophthalmologica       Date:  2017-09-02       Impact factor: 3.250

8.  Prevalence of intermediate-stage age-related macular degeneration in patients with acquired immunodeficiency syndrome.

Authors:  Douglas A Jabs; Mark L Van Natta; Efe Sezgin; Jeong Won Pak; Ronald Danis
Journal:  Am J Ophthalmol       Date:  2015-03-11       Impact factor: 5.258

Review 9.  Complement activation and choriocapillaris loss in early AMD: implications for pathophysiology and therapy.

Authors:  S Scott Whitmore; Elliott H Sohn; Kathleen R Chirco; Arlene V Drack; Edwin M Stone; Budd A Tucker; Robert F Mullins
Journal:  Prog Retin Eye Res       Date:  2014-12-05       Impact factor: 21.198

10.  Summary results and recommendations from the age-related eye disease study.

Authors:  Emily Y Chew; Anne S Lindblad; Traci Clemons
Journal:  Arch Ophthalmol       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.